Page 1 | Search Results | Blood Advances | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Impact of Measurable Residual Disease Clearance Kinetics in Patients with AML Undergoing Intensive Chemotherapy

Wei Ying Jen, Koji Sasaki, Farhad Ravandi, Tapan M. Kadia, Sa A. Wang, Wei Wang, Sanam Loghavi, Naval G. Daver, Courtney D. DiNardo, Ghayas C. Issa, Hussein A. Abbas, Cedric Nasnas, Alex Bataller, Samuel Urrutia, Omer S. Karrar, Sherry A Pierce, Hagop M Kantarjian, Nicholas J. Short

Blood Adv bloodadvances.2024013826.

https://doi.org/10.1182/bloodadvances.2024013826

Published: 2024

Includes: Supplemental data

Journal Articles

Therapy-related chronic myelomonocytic leukemia does not have the high-risk features of a therapy-related neoplasm

Alex Bataller, Georgina Gener-Ricos, Emmanuel Almanza-Huante, Kelly S. Chien, Samuel Urrutia, Alexandre Bazinet, Juan Jose Rodriguez-Sevilla, Danielle Hammond, Koji Sasaki, Koichi Takahashi, Courtney D. DiNardo, Farhad Ravandi, Gautam Borthakur, Tapan M. Kadia, Rashmi Kanagal-Shamanna, Hagop M. Kantarjian, Guillermo Garcia-Manero, Guillermo Montalban-Bravo

Blood Adv (2024) 8 (11): 2695–2706.

https://doi.org/10.1182/bloodadvances.2024012565

Published: 2024

Includes: Supplemental data

Journal Articles

Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax

Alex Bataller, Alexandre Bazinet, Courtney D. DiNardo, Abhishek Maiti, Gautam Borthakur, Naval G. Daver, Nicholas J. Short, Elias J. Jabbour, Ghayas C. Issa, Naveen Pemmaraju, Musa Yilmaz, Guillermo Montalban-Bravo, Koichi Takahashi, Sanam Loghavi, Guillermo Garcia-Manero, Farhad Ravandi, Hagop M. Kantarjian, Tapan M. Kadia

Blood Adv (2024) 8 (4): 927–935.

https://doi.org/10.1182/bloodadvances.2023011757

Published: 2024

Includes: Supplemental data

Journal Articles

Impact of type of induction therapy on outcomes in older adults with AML after allogeneic stem cell transplantation

Blood Adv (2023) 7 (14): 3573–3581.

https://doi.org/10.1182/bloodadvances.2022009632

Published: 2023

Includes: Supplemental data

Journal Articles

Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML

Blood Adv (2023) 7 (6): 933–942.

https://doi.org/10.1182/bloodadvances.2022008316

Published: 2023

Includes: Supplemental data

Journal Articles

Validation of the ALFA-1200 model in older patients with AML treated with intensive chemotherapy

Hussein A. Abbas, Hanxiao Sun, Sherry Pierce, Rashmi Kanagal-Shamanna, Ziyi Li, Musa Yilmaz, Gautam Borthakur, Adam J. DiPippo, Elias Jabbour, Marina Konopleva, Nicholas J. Short, Courtney DiNardo, Naval Daver, Farhad Ravandi, Tapan M. Kadia

Blood Adv (2023) 7 (5): 828–831.

https://doi.org/10.1182/bloodadvances.2022007172

Published: 2023

Includes: Supplemental data

Journal Articles

Validation of ALFA 1200 score in patients with AML >60 years treated with double nucleoside–based low-intensity therapy

Sangeetha Venugopal, Gautam Borthakur, Naval Daver, Courtney D. DiNardo, Naveen Pemmaraju, Nicholas J. Short, Hussein A. Abbas, Guillermo Garcia-Manero, Marina Konopleva, Farhad Ravandi, Tapan M. Kadia

Blood Adv (2022) 6 (19): 5546–5549.

https://doi.org/10.1182/bloodadvances.2021006689

Published: 2022

Journal Articles

High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse

Blood Adv (2022) 6 (13): 4006–4014.

https://doi.org/10.1182/bloodadvances.2022007378

Published: 2022

Includes: Supplemental data

Journal Articles

Gilteritinib combination therapies in pediatric patients with FLT3 -mutated acute myeloid leukemia

David McCall, Michael Roth, Kris M. Mahadeo, Laurie Toepfer, Cesar Nunez, Nicholas J. Short, Naval Daver, Tapan M. Kadia, Courtney DiNardo, Joanna S. Yi, Branko Cuglievan

Blood Adv (2021) 5 (23): 5215–5219.

https://doi.org/10.1182/bloodadvances.2021005164

Published: 2021

Journal Articles

Final results of a phase 2 clinical trial of LCL161, an oral SMAC mimetic for patients with myelofibrosis

Blood Adv (2021) 5 (16): 3163–3173.

https://doi.org/10.1182/bloodadvances.2020003829

Published: 2021

Journal Articles

Single-center experience with venetoclax combinations in patients with newly diagnosed and relapsed AML evolving from MPNs

Lucia Masarova, Courtney D. DiNardo, Prithviraj Bose, Naveen Pemmaraju, Naval G. Daver, Tapan M. Kadia, Helen T. Chifotides, Lingsha Zhou, Gautam Borthakur, Zeev Estrov, Marina Konopleva, Srdan Verstovsek

Blood Adv (2021) 5 (8): 2156–2164.

https://doi.org/10.1182/bloodadvances.2020003934

Published: 2021

Includes: Supplemental data

Journal Articles

Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia

Blood Adv (2021) 5 (7): 1876–1883.

https://doi.org/10.1182/bloodadvances.2020003717

Published: 2021

Includes: Supplemental data

Journal Articles

Prognostic impact of complete remission with MRD negativity in patients with relapsed or refractory AML

Nicholas J. Short, Hind Rafei, Naval Daver, Hyunsoo Hwang, Jing Ning, Jeffrey L. Jorgensen, Tapan M. Kadia, Courtney D. DiNardo, Sa A. Wang, Elias Jabbour, Uday Popat, Betul Oran, Jorge Cortes, Marina Konopleva, Musa Yilmaz, Ghayas C. Issa, Hagop Kantarjian, Farhad Ravandi

Blood Adv (2020) 4 (24): 6117–6126.

https://doi.org/10.1182/bloodadvances.2020002811

Published: 2020

Includes: Supplemental data

Journal Articles

Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia

Nicholas J. Short, Guillermo Montalban-Bravo, Hyunsoo Hwang, Jing Ning, Miguel J. Franquiz, Rashmi Kanagal-Shamanna, Keyur P. Patel, Courtney D. DiNardo, Farhad Ravandi, Guillermo Garcia-Manero, Koichi Takahashi, Marina Konopleva, Naval Daver, Ghayas C. Issa, Michael Andreeff, Hagop Kantarjian, Tapan M. Kadia

Blood Adv (2020) 4 (22): 5681–5689.

https://doi.org/10.1182/bloodadvances.2020003120

Published: 2020

Includes: Supplemental data

Journal Articles

Clinical value of event-free survival in acute myeloid leukemia

Blood Adv (2020) 4 (8): 1690–1699.

https://doi.org/10.1182/bloodadvances.2019001150

Published: 2020

Includes: Supplemental data

Journal Articles

Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens

Blood Adv (2020) 4 (7): 1311–1320.

https://doi.org/10.1182/bloodadvances.2019001267

Published: 2020

Includes: Supplemental data

Journal Articles

Genomic context and TP53 allele frequency define clinical outcomes in TP53 -mutated myelodysplastic syndromes

Blood Adv (2020) 4 (3): 482–495.

https://doi.org/10.1182/bloodadvances.2019001101

Published: 2020

Includes: Supplemental data

Journal Articles

Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs

Preetesh Jain, Hagop Kantarjian, Prajwal C. Boddu, Graciela M. Nogueras-González, Srdan Verstovsek, Guillermo Garcia-Manero, Gautam Borthakur, Koji Sasaki, Tapan M. Kadia, Princy Sam, Hycienth Ahaneku, Susan O’Brien, Zeev Estrov, Farhad Ravandi, Elias Jabbour, Jorge E. Cortes

Blood Adv (2019) 3 (6): 851–861.

https://doi.org/10.1182/bloodadvances.2018025874

Published: 2019

Includes: Supplemental data

Journal Articles

Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis

Prajwal Boddu, Hagop M. Kantarjian, Guillermo Garcia-Manero, Farhad Ravandi, Srdan Verstovsek, Elias Jabbour, Gautam Borthakur, Marina Konopleva, Kapil N. Bhalla, Naval Daver, Courtney D. DiNardo, Christopher B. Benton, Koichi Takahashi, Zeev Estrov, Sherry R. Pierce, Michael Andreeff, Jorge E. Cortes, Tapan M. Kadia

Blood Adv (2017) 1 (17): 1312–1323.

https://doi.org/10.1182/bloodadvances.2017008227

Published: 2017

Includes: Supplemental data

NARROW

Impact of Measurable Residual Disease Clearance Kinetics in Patients with AML Undergoing Intensive Chemotherapy

Therapy-related chronic myelomonocytic leukemia does not have the high-risk features of a therapy-related neoplasm

Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax

Impact of type of induction therapy on outcomes in older adults with AML after allogeneic stem cell transplantation

Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML

Validation of the ALFA-1200 model in older patients with AML treated with intensive chemotherapy

Validation of ALFA 1200 score in patients with AML >60 years treated with double nucleoside–based low-intensity therapy

High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse

Gilteritinib combination therapies in pediatric patients with FLT3 -mutated acute myeloid leukemia

Final results of a phase 2 clinical trial of LCL161, an oral SMAC mimetic for patients with myelofibrosis

Single-center experience with venetoclax combinations in patients with newly diagnosed and relapsed AML evolving from MPNs

Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia

Prognostic impact of complete remission with MRD negativity in patients with relapsed or refractory AML

Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia

Clinical value of event-free survival in acute myeloid leukemia

Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens

Genomic context and TP53 allele frequency define clinical outcomes in TP53 -mutated myelodysplastic syndromes

Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs

Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only